CONSHOHOCKEN, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic ...

Madrigal Pharma was the first drugmaker to bring a treatment for metabolic dysfunction-associated steatohepatitis (MASH) to market, and has now signed a major alliance with China's Ribo Life Science ...

Madrigal Pharmaceuticals MDGL announced an exclusive global licensing agreement with Suzhou Ribo Life Science Co. Ltd. (Ribo) and its subsidiary, Ribocure Pharmaceuticals AB (Ribocure), covering six ...

Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra® (resmetirom) as the foundational ...

Madrigal Pharmaceuticals (MASH) has reached an exclusive licensing agreement with China-based Suzhou Ribo Life Science to jointly develop treatments targeting a liver disease called metabolic ...

SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced ...

Extra-large sea scallops are pan-seared in olive oil, then served atop a cheesy mash of baby peas with a drizzle of fragrant chive oil for a special meal. Emeril Lagassé is an American celebrity chef, ...

Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra - (resmetirom) as the foundational ...

Interested in learning Python but don't know where to start? I'll walk you through the basics of the ever-popular programming language step-by-step. In an hour or so, you'll go from zero to writing ...

Madrigal Pharmaceuticals is continuing to splash the cash this year on liver disease drugs it can combine with its own potential blockbuster Rezdiffra. Just weeks after betting $50 million on a DGAT2i ...

QUEBEC, Feb. 19, 2026 /CNW/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced positive results from a follow-up preclinical study evaluating ...